Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) is a medical diagnostics company developing the Symphony near-patient testing platform and the Symphony IL-6 Test for sepsis triage and monitoring. The BJDX news feed features company announcements that trace Bluejay’s progress across clinical development, manufacturing partnerships, regulatory planning, and financing activities related to its critical-care diagnostics strategy.
Readers can follow updates on the SYMON Clinical Study Program, including the SYMON-I pilot study and the pivotal SYMON-II trial, which are designed to evaluate IL-6 as a prognostic biomarker for mortality and other endpoints in sepsis and ICU patients. News items describe how Bluejay plans to use data from these studies to support a future 510(k) submission for the Symphony IL-6 test and to advance its goal of providing rapid, near-patient diagnostics for critical care.
The BJDX news stream also covers manufacturing and supply-chain developments, such as amendments to the company’s Master Service and Master Supply Agreements with SanyoSeiko Co., Ltd. and updates on its amended license and supply arrangements with Toray Industries, Inc. These releases detail SanyoSeiko’s expanded role in analyzer and cartridge manufacturing, as well as Bluejay’s efforts to secure alternative cartridge manufacturing capabilities and regulatory-grade supply chain readiness.
In addition, Bluejay’s news includes capital markets and corporate updates, including private placements, warrant inducement transactions, and a reverse stock split, along with commentary on how the company intends to use proceeds to fund clinical studies, regulatory activities, and working capital. Investors and observers can use this page to review historical press releases, clinical milestones, manufacturing agreements, and financing disclosures that shape the company’s development of the Symphony IL-6 test and its broader critical-care diagnostics platform.
Bluejay Diagnostics (NASDAQ: BJDX) has entered a collaborative agreement with Blood Centers of America (BCA) to address unmet needs in the blood and hospital markets using its Symphony Platform. This partnership allows Bluejay to access BCA's extensive network of over 60 blood centers, potentially enhancing the delivery of critical care solutions. The collaboration aims to support clinical studies and explore Symphony's applications in the blood supply industry. Bluejay's Symphony IL-6 Test, designed for rapid sepsis triage, will play a pivotal role in this initiative, addressing urgent patient care needs.
Bluejay Diagnostics (NASDAQ: BJDX) reported its financial results for the quarter and nine months ending September 30, 2022, highlighting a net loss of $6.9 million, with a net loss per share of $0.34. While revenues saw a slight increase of $250,000 compared to 2021, there were no sales in Q3 2022. R&D expenses rose significantly to $2.8 million as the company expands its clinical program for the Symphony IL-6 test, which has shown promising results in identifying COVID-19 patients at risk for severe illness. Cash reserves stood at $13.3 million, expected to support operations for 12 months.
Bluejay Diagnostics (NASDAQ: BJDX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, at the Lotte Palace Hotel, New York City. CEO Neil Dey and CFO Kenneth Fisher will present on September 13 at 10:30 AM ET. The management team will also engage in one-on-one meetings with investors. Bluejay focuses on rapid, cost-effective diagnostic testing, with its first candidate, an IL-6 Test for sepsis triage, promising results in about 20 minutes. For further details, visit bluejaydx.com.
Bluejay Diagnostics (NASDAQ: BJDX) will host a virtual Key Opinion Leader event on August 25, 2022, focusing on IL-6 Testing in Critical Care settings and its relevance in managing COVID-19 and respiratory failure.
The discussion will feature experts Nathan I. Shapiro, MD, MPH, and Bryan D. Kraft, MD, reflecting on patient care and the Symphony IL-6 test’s potential to enhance clinical decision-making. A live Q&A will follow. The Symphony System aims to provide rapid, near-patient testing, delivering results in approximately 20 minutes.
Bluejay Diagnostics (NASDAQ: BJDX) announced promising results for its Symphony IL-6 Test at AACC 2022, demonstrating a 98% Negative Predictive Value (NPV) for identifying COVID-19 patients at risk for severe illness. The test's clinical sensitivity was found to be 89% and specificity 64%, showing comparable performance to existing FDA EUA-approved tests. Key advantages include faster results (<20 minutes), ease of use, and low cost, positioning it as a valuable tool in critical care settings.
Bluejay Diagnostics (NASDAQ: BJDX) reported financial results for Q2 2022, highlighting a net loss of $1.9 million, or $0.10 per share. Cash and cash equivalents fell to $15.3 million from $19.0 million at year-end 2021. The company is advancing its Symphony IL-6 Test, with plans for FDA marketing application submission in Q4 2022. Significant increases in R&D and G&A expenses reflect investment in clinical studies and scalable infrastructure. The Symphony System aims to deliver rapid testing results in 20 minutes, enhancing patient care for life-threatening diseases.
Bluejay Diagnostics (NASDAQ: BJDX) has completed its clinical studies for the Symphony IL-6 Test, a key milestone towards submitting a de Novo Marketing Application to the FDA by year-end. The studies included a reference range study and validation studies, the results of which will be revealed at the AACC Annual Scientific Meeting from July 26-28, 2022. The Symphony System aims to provide rapid, near-patient testing with results in approximately 20 minutes, enhancing decision-making in critical care settings.
Bluejay Diagnostics (NASDAQ: BJDX) announced that the FDA has agreed to consider its De Novo submission plan for the Symphony IL-6 Test. This follows feedback on a January 2022 pre-submission package indicating potential for the test's regulatory pathway. CEO Neil Dey expressed optimism about advancing the Symphony IL-6 Test towards FDA marketing application, expected by year-end 2022. The Symphony System aims to provide rapid, efficient patient testing with results in approximately 20 minutes, targeting improved disease management.
Bluejay Diagnostics (NASDAQ: BJDX) announced its financial results for Q1 2022, reporting a cash position of $17.1 million. This is down from $19.0 million at the end of 2021, but expected to support operations until the anticipated regulatory approval and launch of its Symphony IL-6 Test. The company saw a substantial rise in R&D expenses to $695,000 from $24,000 year-over-year, reflecting ongoing clinical studies. Net loss for the quarter was $2.0 million, or $0.10 per share, compared to $194,000, or $0.06 per share in Q1 2021.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has appointed Edwin “Ed” E. Rule as Vice President of Regulatory, Quality, and Compliance. With over 15 years of experience in medical device regulations, Mr. Rule is expected to enhance the company's efforts towards its Symphony IL-6 Test marketing application to the FDA due later this year. The Symphony System aims to provide rapid, near-patient diagnostic testing to improve patient outcomes in critical care settings.
Mr. Rule's expertise will be pivotal in navigating regulatory processes and ensuring product compliance.